Latest news with #ICUMedical
Yahoo
5 days ago
- Business
- Yahoo
ICU Medical's (NASDAQ:ICUI) Q2: Beats On Revenue
Medical device company ICU Medical (NASDAQ:ICUI) reported Q2 CY2025 results exceeding the market's revenue expectations , but sales fell by 8% year on year to $548.9 million. Its GAAP profit of $1.43 per share was significantly above analysts' consensus estimates. Is now the time to buy ICU Medical? Find out in our full research report. ICU Medical (ICUI) Q2 CY2025 Highlights: Revenue: $548.9 million vs analyst estimates of $539.7 million (8% year-on-year decline, 1.7% beat) EPS (GAAP): $1.43 vs analyst estimates of -$0.47 (significant beat) Adjusted EBITDA: $100.3 million vs analyst estimates of $90.8 million (18.3% margin, 10.5% beat) EPS (GAAP) guidance for the full year is $7 at the midpoint, beating analyst estimates by 443% EBITDA guidance for the full year is $392.5 million at the midpoint, above analyst estimates of $387.5 million Operating Margin: 1.9%, down from 4.1% in the same quarter last year Free Cash Flow was -$8.49 million, down from $62.67 million in the same quarter last year Market Capitalization: $3.2 billion Vivek Jain, ICU Medical's Chief Executive Officer, said, 'Second quarter results were generally in line with our expectations." Company Overview Founded in 1984 and named for its initial focus on intensive care units, ICU Medical (NASDAQ:ICUI) develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Thankfully, ICU Medical's 14.2% annualized revenue growth over the last five years was solid. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. ICU Medical's recent performance shows its demand has slowed as its annualized revenue growth of 1.4% over the last two years was below its five-year trend. This quarter, ICU Medical's revenue fell by 8% year on year to $548.9 million but beat Wall Street's estimates by 1.7%. Looking ahead, sell-side analysts expect revenue to decline by 10.4% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will face some demand challenges. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. ICU Medical was profitable over the last five years but held back by its large cost base. Its average operating margin of 3% was weak for a healthcare business. Analyzing the trend in its profitability, ICU Medical's operating margin decreased by 4.6 percentage points over the last five years, but it rose by 4.1 percentage points on a two-year basis. Still, shareholders will want to see ICU Medical become more profitable in the future. In Q2, ICU Medical generated an operating margin profit margin of 1.9%, down 2.2 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Sadly for ICU Medical, its EPS declined by 19.1% annually over the last five years while its revenue grew by 14.2%. This tells us the company became less profitable on a per-share basis as it expanded. We can take a deeper look into ICU Medical's earnings to better understand the drivers of its performance. As we mentioned earlier, ICU Medical's operating margin declined by 4.6 percentage points over the last five years. Its share count also grew by 14.9%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders. In Q2, ICU Medical reported EPS at $1.43, up from negative $0.88 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects ICU Medical to improve its earnings losses. Analysts forecast its full-year EPS of negative $1.52 will advance to negative $1.02. Key Takeaways from ICU Medical's Q2 Results We were impressed by how significantly ICU Medical blew past analysts' EPS expectations this quarter. We were also excited its full-year EPS guidance outperformed Wall Street's estimates by a wide margin. Zooming out, we think this was a good print with some key areas of upside. The market seemed to be hoping for more, and the stock traded down 1.7% to $128 immediately following the results. Should you buy the stock or not? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
11-07-2025
- Business
- Yahoo
Lantheus, ICU Medical, Haemonetics, CONMED, and Astrana Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Medical Devices & Supplies - Imaging, Diagnostics company Lantheus (NASDAQ:LNTH) fell 3.1%. Is now the time to buy Lantheus? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company ICU Medical (NASDAQ:ICUI) fell 3.3%. Is now the time to buy ICU Medical? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Haemonetics (NYSE:HAE) fell 3.4%. Is now the time to buy Haemonetics? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Diversified company CONMED (NYSE:CNMD) fell 3.7%. Is now the time to buy CONMED? Access our full analysis report here, it's free. Healthcare Technology for Providers company Astrana Health (NASDAQ:ASTH) fell 3.3%. Is now the time to buy Astrana Health? Access our full analysis report here, it's free. CONMED's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. CONMED is down 23.3% since the beginning of the year, and at $51.67 per share, it is trading 33.4% below its 52-week high of $77.54 from November 2024. Investors who bought $1,000 worth of CONMED's shares 5 years ago would now be looking at an investment worth $708.88. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
10-06-2025
- Business
- Yahoo
3 Reasons to Avoid ICUI and 1 Stock to Buy Instead
Over the last six months, ICU Medical's shares have sunk to $136.25, producing a disappointing 14.9% loss while the S&P 500 was flat. This may have investors wondering how to approach the situation. Is now the time to buy ICU Medical, or should you be careful about including it in your portfolio? Dive into our full research report to see our analyst team's opinion, it's free. Even though the stock has become cheaper, we don't have much confidence in ICU Medical. Here are three reasons why you should be careful with ICUI and a stock we'd rather own. Long-term growth is the most important, but within healthcare, a stretched historical view may miss new innovations or demand cycles. ICU Medical's recent performance shows its demand has slowed as its annualized revenue growth of 2.2% over the last two years was below its five-year trend. Forecasted revenues by Wall Street analysts signal a company's potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect ICU Medical's revenue to drop by 12.3%, a decrease from its 14.6% annualized growth for the past five years. This projection is underwhelming and suggests its products and services will face some demand challenges. Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for ICU Medical, its EPS declined by 1.1% annually over the last five years while its revenue grew by 14.6%. This tells us the company became less profitable on a per-share basis as it expanded. We cheer for all companies serving everyday consumers, but in the case of ICU Medical, we'll be cheering from the sidelines. Following the recent decline, the stock trades at 18.9× forward P/E (or $136.25 per share). This valuation tells us a lot of optimism is priced in - you can find better investment opportunities elsewhere. We'd suggest looking at a dominant Aerospace business that has perfected its M&A strategy. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
18-05-2025
- Business
- Associated Press
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc.
NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. ('ICU' or the 'Company') (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether ICU and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 22, 2025, ICU disclosed receipt of a warning letter from the U.S. Food and Drug Administration ('FDA'), citing unauthorized changes to two of the Company's infusion pump products. The FDA's warning letter stated that the pumps were 'adulterated' and 'misbranded,' noting that the Company's modifications 'can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, [and] alarm functionality.' The FDA further stated that these changes may have significantly impacted the safety and efficacy of the devices, raising concerns about the adequacy of ICU's regulatory disclosures. On this news, ICU's stock price fell $6.04 per share, or 4.42%, to close at $130.68 per share on April 22, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP
Yahoo
10-05-2025
- Business
- Yahoo
ICUI Q1 Earnings Call: Product Upgrades and Tariff Headwinds Shape Outlook
Medical device company ICU Medical (NASDAQ:ICUI) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 5.8% year on year to $599.5 million. Its non-GAAP profit of $1.72 per share was 34.4% above analysts' consensus estimates. Is now the time to buy ICUI? Find out in our full research report (it's free). Revenue: $599.5 million vs analyst estimates of $567.2 million (5.8% year-on-year growth, 5.7% beat) Adjusted EPS: $1.72 vs analyst estimates of $1.28 (34.4% beat) Adjusted EBITDA: $99.43 million vs analyst estimates of $88.48 million (16.6% margin, 12.4% beat) Operating Margin: 4.9%, up from 1% in the same quarter last year Free Cash Flow Margin: 6.1%, similar to the same quarter last year Market Capitalization: $3.52 billion ICU Medical's first quarter performance was driven by growth across all core business segments, with management highlighting momentum in consumables, infusion systems, and vital care. CEO Vivek Jain attributed the broad-based expansion to new global customer implementations and positive trends in key markets such as oncology and home infusion. Jain noted, 'Our consumables business saw rapid growth in niche markets and benefited from earlier-than-anticipated hardware installs in IV Systems.' Looking ahead, management's guidance is shaped by several moving pieces, including the impact of newly implemented tariffs and ongoing product upgrades. CFO Brian Bonnell stated that while the company aims to offset most tariff costs through mitigation measures and currency tailwinds, 'there is probably $5 to $10 million of unmitigated residual impact from tariffs' in 2025. Jain emphasized continued investment in pump innovation and compliance initiatives, positioning the company for a multi-year upgrade cycle and supporting reliable revenue growth. Management pointed to consistent execution and ongoing product investment as key drivers in the quarter, while also flagging regulatory and trade-related costs as areas of focus for the remainder of the year. Consumables business acceleration: Growth in the consumables segment was supported by new global customer implementations, improved product pricing, and demand in specialized markets like oncology and home infusion. Management identified group purchasing organization (GPO) activity and earlier contract resets as contributing factors. IV Systems product cycle: The infusion systems segment benefited from increased utilization of dedicated sets and some early hardware installs, though management clarified that widespread adoption of new products like PlumDuo is expected later in the year. Quality and regulatory remediation: Management described significant efforts to address quality issues in legacy products, including extensive remediation of MedFusion and CAD pumps and ongoing work to secure new regulatory clearances. CEO Vivek Jain stated, 'Modern devices and high compliance are table stakes in our industry.' Tariff and supply chain impact: The introduction of tariffs on products from Costa Rica, China, and Mexico will increase costs in 2025. While some mitigations are in place, management explained that tariffs on Costa Rica-sourced pumps represent the largest exposure, and the company has begun adjusting supply chains where possible. Joint venture formation: ICU Medical completed the formation of a joint venture with Otsuka Pharmaceutical Factory for IV Solutions, which is expected to provide long-term product and technology access. Management noted this is neutral to current earnings but strategically significant for the U.S. market. Management's outlook for the year centers on executing product upgrades, navigating tariff costs, and maintaining operational discipline as the company enters a period of portfolio refresh and supply chain adjustment. Product upgrade cycle: The company expects a multi-year upgrade cycle for its installed base of infusion pumps, with the launch of PlumSolo and PlumDuo positioned to drive adoption as customer contracts come up for renewal. Tariff mitigation efforts: Management is pursuing a range of mitigation strategies to offset new tariff costs, including supply chain adjustments, price renegotiations, and cost controls. However, residual headwinds of $5–10 million may persist if additional offsets are not identified. Regulatory compliance focus: Continued investment in quality remediation and securing new regulatory clearances for legacy product lines is expected to support both compliance and future product competitiveness, reducing operational risk. Jayson Bedford (Raymond James): Asked about sources of consumables growth and whether pricing or niche market demand was driving results. Management pointed to oncology and renal markets, GPO activity, and clarified that pricing was not the primary factor. Brett Fishbin (KeyBanc): Inquired about the geographic structure of tariff exposure and opportunities for further mitigation. CFO Brian Bonnell explained that Costa Rica-sourced products are the largest exposure, with ongoing actions to reduce impact from China and Mexico. Larry Solow (CJS Securities): Questioned the expected pace and customer receptivity to the new PlumSolo and PlumDuo pumps. CEO Vivek Jain described a gradual upgrade cycle, emphasizing the installed base's readiness for refresh due to device age. Michael Toomey (Jefferies): Asked if recent growth in infusion systems reflected market share gains or underlying market strength. Management cited improved utilization and earlier hardware installs as key contributors. Joseph Conway (Jefferies): Sought detail on marketing strategies for new pump products and expectations for customer adoption patterns. Jain noted the importance of safety features and flexibility for both single and mixed device environments. In the coming quarters, the StockStory team will be monitoring (1) the pace of customer adoption and upgrade activity for the PlumSolo and PlumDuo infusion pumps, (2) the effectiveness of tariff mitigation strategies and any adjustments to supply chain or pricing, and (3) regulatory progress on clearing legacy product lines. Progress on these fronts will be critical for sustaining revenue growth and managing cost pressures. ICU Medical currently trades at a forward P/E ratio of 19.8×. Should you load up, cash out, or stay put? See for yourself in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
